Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Could thrombin generation be a better biomarker?
Nossair F et al. ASH 2018, Poster 3788
Key clinical point: Thrombin generation should be further evaluated as a biomarker for predicting bleeding severity in patients with nonsevere hemophilia.
Major finding: Compared with baseline factor level, all thrombin generation values had a higher sensitivity to predict bleeding severity (57%-62% versus 29%).
Study details: The study included 81 patients with mild or moderate hemophilia A or B and compared biomarkers for differentiating between bleeding phenotype severities.
Disclosures: The study was supported by grants from Novo Nordisk. Dr. Nossair reported financial disclosures related to Novo Nordisk.
Citation:
Nossair F et al. ASH 2018, Poster 3788.